Key Metrics

Market Cap
Total Shares Outstanding
Book Value
PE Ratio

PS Ratio
PB Ratio
Forward PE Ratio
ROIC

Return on Aseets
Return on Equity
Dividend
Dividend Yield

Balancesheet Metrics

Total Assets
Total Liability
Assets-to-Libability Ratio

Total Current Assets
Total Current Liability
Current Ratio

Quick Ratio
Debt to Equity Ratio

Income Statement Metrics

Net Income
EPS
EBITA

Gross Profit
Gross Profit Margin
Operating Margin

Net Profit Margin

Price Metrics

5 Days MA
10 Days MA
20 Days MA
50 Days MA
200 Days MA

52 Weeks High
52 Weeks low
All Time High

RSI
MACD

Share Stats

Shares Float
Shares Short

% Short
% Insider

% Institutions

% Institutions

News

Sean Whelan Appointed to Board of DirectorsANN ARBOR, Mich., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that Sean Whelan has been appointed to its Board of Directors to fill the vac...
ANN ARBOR, Mich., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that Sean Whelan has been appointed to its Board of Directors to fill the vacancy created by the resignation of Christopher Wolfenberg. Robert Cohen, Zomedica’s Chief Executive Officer, commented that: “We all are very pleased to be joined by an executive with Sean’s sterling background. His broad and deep experience and expertise in financial matters, as well as his previous service with publicly listed companies, will be an excellent addition to our Board. I look forward to Sean assuming the Chairmanship of our Audit Committee, and to working with him on a wide variety of issues as Zomedica progresses. I also would like to thank Chris Wolfenberg for his service on the Board and for his valuable counsel during the time that we worked together.” Mr. Whelan presently is the Chief Executive Officer of Encore Rehabilitation Services, a provider of outcome-driven therapy services and associated compliance and revenue cycle support services. He also previously served as the Company’s CFO from 2017 to 2018. From 2019 to 2020, Mr. Whelan served as CFO of Smile America Partners, and from 2018 to 2019 as CFO of Bedrock Manufacturing, LLC. He served from 2010 to 2016 as CFO, secretary, treasurer, and a director of Diplomat, Inc. (NYSE: DPLO), a then publicly traded specialty pharmacy, where he was responsible for finance, external reporting, and investor relations, strategy and M&A. Mr. Whelan served from 2007 to 2010 as CFO of InfuSystem Holdings Inc., a publicly traded health care services company. Prior to his various healthcare executive roles, Mr. Whelan held senior finance positions with Ford Motor Company from 1996 through 2007, including serving as accounting director for Automotive Components Holdings, LLC, a then Ford subsidiary. Mr. Whelan began his career with Deloitte in 1994, serving a diverse set of audit clients in the firm’s Detroit office, and earned his CPA license while with the firm. He holds Bachelor of Business Administration and Master of Accounting degrees, both from the University of Michigan’s Ross School of Business. Mr. Whelan also presently serves (since 2019) on the Board of Directors of OptioRx, a specialty pharmacy company. Mr. Whelan commented that: “As a dog and cat owner, I am excited by the prospects of Zomedica’s present and future products. And as a business executive, I am thrilled to partner with Rob and the Board to help nurture that growth.” About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com. Follow Zomedica Email Alerts: http://investors.zomedica.comLinkedIn: https://www.linkedin.com/company/zomedica Reader Advisory Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact: PCG Advisory Kirin Smith, President ksmith@pcgadvisory.com +1 646.823.8656
DPLO | globenewswire | about 4 years ago | Neutral

Sean Whelan Appointed to Board of DirectorsANN ARBOR, Mich., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that Sean Whelan has been appointed to its Board of Directors to fill the vacan...
ANN ARBOR, Mich., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that Sean Whelan has been appointed to its Board of Directors to fill the vacancy created by the resignation of Christopher Wolfenberg. Robert Cohen, Zomedica’s Chief Executive Officer, commented that: “We all are very pleased to be joined by an executive with Sean’s sterling background. His broad and deep experience and expertise in financial matters, as well as his previous service with publicly listed companies, will be an excellent addition to our Board. I look forward to Sean assuming the Chairmanship of our Audit Committee, and to working with him on a wide variety of issues as Zomedica progresses. I also would like to thank Chris Wolfenberg for his service on the Board and for his valuable counsel during the time that we worked together.” Mr. Whelan presently is the Chief Executive Officer of Encore Rehabilitation Services, a provider of outcome-driven therapy services and associated compliance and revenue cycle support services. He also previously served as the Company’s CFO from 2017 to 2018. From 2019 to 2020, Mr. Whelan served as CFO of Smile America Partners, and from 2018 to 2019 as CFO of Bedrock Manufacturing, LLC. He served from 2010 to 2016 as CFO, secretary, treasurer, and a director of Diplomat, Inc. (NYSE: DPLO), a then publicly traded specialty pharmacy, where he was responsible for finance, external reporting, and investor relations, strategy and M&A. Mr. Whelan served from 2007 to 2010 as CFO of InfuSystem Holdings Inc., a publicly traded health care services company. Prior to his various healthcare executive roles, Mr. Whelan held senior finance positions with Ford Motor Company from 1996 through 2007, including serving as accounting director for Automotive Components Holdings, LLC, a then Ford subsidiary. Story continues Mr. Whelan began his career with Deloitte in 1994, serving a diverse set of audit clients in the firm’s Detroit office, and earned his CPA license while with the firm. He holds Bachelor of Business Administration and Master of Accounting degrees, both from the University of Michigan’s Ross School of Business. Mr. Whelan also presently serves (since 2019) on the Board of Directors of OptioRx, a specialty pharmacy company. Mr. Whelan commented that: “As a dog and cat owner, I am excited by the prospects of Zomedica’s present and future products. And as a business executive, I am thrilled to partner with Rob and the Board to help nurture that growth.” About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com. Follow Zomedica Email Alerts: http://investors.zomedica.com LinkedIn: https://www.linkedin.com/company/zomedica Reader Advisory Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition. Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Investor Relations Contact: PCG Advisory Kirin Smith, President ksmith@pcgadvisory.com +1 646.823.8656
DPLO ZOM | finance.yahoo | about 4 years ago | Neutral

NYSE: DPLO Investor Notice: Lawsuit against Diplomat Pharmacy Inc announced by Shareholders FoundationSAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Diplomat Pharmacy Inc (NYSE: DPLO). Investors, who purchased shares of Diplomat Pharmacy Inc (NYSE: DPLO), have certain options and should cont...
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Diplomat Pharmacy Inc (NYSE: DPLO). Investors, who purchased shares of Diplomat Pharmacy Inc (NYSE: DPLO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that Diplomat Pharmacy Inc had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017, that consequently, Diplomat Pharmacy Inc would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions, that due to the foregoing, Diplomat Pharmacy Inc would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior, and that as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Those who purchased Diplomat Pharmacy Inc (NYSE: DPLO) shares should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 mail@shareholdersfoundation.com 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
DPLO | globenewswire | about 6 years ago | Neutral

APRIL 25 DEADLINE: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Diplomat Pharmacy, Inc. (DPLO) and Encourages DPLO Investors to Contact the FirmNEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Diplomat Pharmacy, Inc. (NYSE: DP...
NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Diplomat Pharmacy, Inc. (NYSE: DPLO) securities between February 26, 2018 and February 21, 2019 (the “Class Period”). Investors have until April 25, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that throughout the class period defendants made false and/or misleading statements and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. If you purchased Diplomat securities during the Class Period or continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Diplomat lawsuit, please go to https://bespc.com/dplo/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.comwww.bespc.com
DPLO | globenewswire | about 6 years ago | Neutral

APRIL 25 DEADLINE: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Diplomat Pharmacy, Inc. (DPLO) and Encourages DPLO Investors to Contact the FirmNEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Diplomat Pharmacy, Inc. (NYSE: DP...
NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Diplomat Pharmacy, Inc. (NYSE: DPLO) securities between February 26, 2018 and February 21, 2019 (the “Class Period”). Investors have until April 25, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that throughout the class period defendants made false and/or misleading statements and/or failed to disclose that: (1) Diplomat downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge of approximately $630 million relating to its PBM business and the 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. If you purchased Diplomat securities during the Class Period or continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Diplomat lawsuit, please go to https://bespc.com/dplo/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.comwww.bespc.com
DPLO | globenewswire | about 6 years ago | Neutral

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DPLO, CVS, UMC and AAPLNEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. D...
NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. Diplomat Pharmacy, Inc. (NYSE: DPLO) Class Period: February 26, 2018 to February 21, 2019 Lead Plaintiff Deadline: April 25, 2019 The lawsuit alleges that Diplomat Pharmacy, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Get additional information about the DPLO lawsuit: http://www.kleinstocklaw.com/pslra-1/diplomat-pharmacy-inc-loss-submission-form?wire=3 CVS Health Corporation (NYSE: CVS) Class Period: May 21, 2015 to February 20, 2019 Lead Plaintiff Deadline: April 26, 2019 The complaint alleges that during the class period CVS Health Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) CVS Health’s financial condition and expected earnings were deteriorating as a result of rising costs and poor results associated with the Omnicare Acquisition; and (ii) as a result, CVS Health’s public statements were materially false and misleading at all relevant times. Get additional information about the CVS lawsuit: http://www.kleinstocklaw.com/pslra-1/cvs-health-corporation-loss-submission-form?wire=3 United Microelectronics Corporation (NYSE: UMC) Class Period: October 28, 2015 to November 1, 2018 Lead Plaintiff Deadline: May 13, 2019 During the class period, United Microelectronics Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) UMC conspired with Fujian to steal trade secrets from Micron relating to its research and development of Dynamic Random-Access Memory ("DRAM"); (ii) UMC hired former Micron employees for the purpose of stealing such information from Micron; (iii) the foregoing conduct placed UMC and certain of its employees at an increased risk of criminal and regulatory investigation by the U.S. government; and (iv) as a result, UMC’s public statements were materially false and misleading at all relevant times. Get additional information about the UMC lawsuit: http://www.kleinstocklaw.com/pslra-1/united-microelectronics-corporation-loss-submission-form?wire=3 Apple Inc. (NASDAQGS: AAPL) Class Period: November 2, 2018 to January 2, 2019 Lead Plaintiff Deadline: June 17, 2019 The lawsuit alleges that throughout the class period, Apple Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the U.S.-China trade war had negatively impacted demand for iPhones and Apple’s pricing power in greater China, one of Apple’s most important growth markets; (b) the rate at which Apple customers were replacing their batteries in older iPhones rather than purchasing new iPhones was negatively impacting Apple’s iPhone sales growth; (c) as a result of slowing demand, Apple had slashed production orders from suppliers for the new 2018 iPhone models and cut prices to reduce inventory; (d) unit sales for iPhone and other hardware was relevant to investors and the Company’s financial performance, and the decision to withhold such unit sales was designed to and would mask declines in unit sales of the Company’s flagship product; and (e) as a result of the foregoing, defendants lacked a reasonable basis in fact when issuing the Company’s revenue outlook for the first quarter 2019 and/or making the related statements concerning demand for its products, as Apple’s business metrics and financial prospects were not as strong as defendants had led the market to believe. Get additional information about the AAPL lawsuit: http://www.kleinstocklaw.com/pslra-1/apple-inc-loss-submission-form-2?wire=3 Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided. J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: J. Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
CVS DPLO UMC | globenewswire | about 6 years ago | Neutral

DEADLINE THURSDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Diplomat Pharmacy, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmLOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Diplomat Pharmacy, Inc. (“Diplomat” or “the Company”) (NYSE: DPLO) for violations of §§10(b) and 20(a) of the Securities Exchan...
LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Diplomat Pharmacy, Inc. (“Diplomat” or “the Company”) (NYSE: DPLO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between February 26, 2018 and February 21, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before April 25, 2019. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Diplomat downplayed its success in integrating its PBM business, which included LDI Integrated and National Pharmaceutical, companies it acquired in 2017. As a result, the Company had to record a non-cash impairment charge of $630 million related to the PBM business and its acquisitions. Based on this charge, the Company withdrew its 2019 full-year outlook. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Diplomat, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq., Sherin Mahdavian, Esq., www.schallfirm.com Office: 310-301-3335 Cell: 424-303-1964 info@schallfirm.com SOURCE: The Schall Law Firm
DPLO | globenewswire | about 6 years ago | Neutral

CLASS ACTION UPDATE for DPLO, WTW, EB and AAPL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersNEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court an...
NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you. Diplomat Pharmacy, Inc. (NYSE: DPLO) Class Period: February 26, 2018 - February 21, 2019 Lead Plaintiff Deadline: April 25, 2019 Join the action: https://www.zlk.com/pslra-1/diplomat-pharmacy-inc-loss-form?wire=3 About the lawsuit: Throughout the class period, Diplomat Pharmacy, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. To learn more about the Diplomat Pharmacy, Inc. class action contact jlevi@levikorsinsky.com. Weight Watchers International, Inc. (NASDAQ: WTW) Class Period: May 4, 2018 - February 26, 2019 Lead Plaintiff Deadline: May 3, 2019 Join the action: https://www.zlk.com/pslra-1/weight-watchers-international-inc-loss-form?wire=3 About the lawsuit: Weight Watchers International, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (a) Weight Watchers was experiencing diminished subscriber demand attributable due to the onslaught of new competing smartphone fitness apps, meal-delivery services, and other tech advances, which were driving down Weight Watchers’ new subscriber growth and its subscriber retention rates; (b) diminished subscriber growth, when coupled with the much larger number of fourth quarter subscription lapses that Weight Watchers typically experiences, made it highly unlikely that the Company would retain four million subscribers by the end of 2018; (c) Weight Watchers was not on track to grow its subscriber count to five million or to drive annual revenues to more than $2 billion by the end of 2020; (d) a decreased subscriber count would result in decreased revenues and profits; and (e) as a result, Defendants’ statements about Weight Watchers’ business metrics and financial prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. To learn more about the Weight Watchers International, Inc. class action contact jlevi@levikorsinsky.com. Eventbrite, Inc. (NYSE: EB) Class Period: Purchasers of shares (a) pursuant and/or traceable to the Company’s September 2018 initial public offering; and/or (b) between September 20, 2018 and March 7, 2019 Lead Plaintiff Deadline: June 17, 2019 Join the action: https://www.zlk.com/pslra-1/eventbrite-inc-loss-form?wire=3 About the lawsuit: During the class period, Eventbrite, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s migration of customers from Ticketfly to Eventbrite was progressing slower than expected; (2) as a result, the Ticketfly integration would take longer than expected; (3) as a result, the Company’s revenue and growth would be negatively impacted; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. To learn more about the Eventbrite, Inc. class action contact jlevi@levikorsinsky.com. Apple Inc. (NASDAQGS: AAPL) Class Period: November 2, 2018 - January 2, 2019 Lead Plaintiff Deadline: June 17, 2019 Join the action: https://www.zlk.com/pslra-1/apple-inc-loss-form?wire=3 About the lawsuit: Apple Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (a) the U.S.-China trade war had negatively impacted demand for iPhones and Apple’s pricing power in greater China, one of Apple’s most important growth markets; (b) the rate at which Apple customers were replacing their batteries in older iPhones rather than purchasing new iPhones was negatively impacting Apple’s iPhone sales growth; (c) as a result of slowing demand, Apple had slashed production orders from suppliers for the new 2018 iPhone models and cut prices to reduce inventory; (d) unit sales for iPhone and other hardware was relevant to investors and the Company’s financial performance, and the decision to withhold such unit sales was designed to and would mask declines in unit sales of the Company’s flagship product; and (e) as a result of the foregoing, defendants lacked a reasonable basis in fact when issuing the Company’s revenue outlook for the first quarter 2019 and/or making the related statements concerning demand for its products, as Apple’s business metrics and financial prospects were not as strong as defendants had led the market to believe. To learn more about the Apple Inc. class action contact jlevi@levikorsinsky.com. You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 55 Broadway, 10th Floor New York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
DPLO EB WTW | globenewswire | about 6 years ago | Neutral

DPLO FINAL DEADLINE REMINDER: Rosen Law Firm Reminds Diplomat Pharmacy, Inc. Investors of Important April 25th Deadline in Securities Class Action Filed by the Firm – DPLONEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Diplomat Pharmacy, Inc. (NYSE: DPLO) from February 26, 2018 through February 21, 2019, inclusive (the “Class Period”) of the April 25, 2019 lead plaintiff deadlin...
NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Diplomat Pharmacy, Inc. (NYSE: DPLO) from February 26, 2018 through February 21, 2019, inclusive (the “Class Period”) of the April 25, 2019 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Diplomat investors under the federal securities laws. To join the Diplomat class action, go to https://www.rosenlegal.com/cases-register-1515.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 25, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-register-1515.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or cases@rosenlegal.com. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com cases@rosenlegal.com www.rosenlegal.com
DPLO | globenewswire | about 6 years ago | Neutral

Class Action Alert CAG, DPLO & AVEO Bronstein, Gewirtz & Grossman, LLCNEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may conta...
NEW YORK, April 23, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Conagra Brands, Inc. (NYSE: CAG) Class Period: June 27, 2018 - December 19, 2018, and/or purchased shares of Conagra’s common stock pursuant and/or traceable to Conagra’s secondary public offering commenced on or about October 9, 2018 (“SPO”) Deadline: April 23, 2019 For more info:www.bgandg.com/cag The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that material information about Conagra’s acquisition of Pinnacle Foods, Inc. (“Pinnacle”), including that: (1) Conagra inadequately performed proper due diligence in connection with the acquisition of Pinnacle; (2) the performance of Pinnacle’s three leading brands was not deteriorating due to intensified competition, but to self-inflicted subpar innovation and executional missteps; (3) Pinnacle’s business was performing so poorly that it had resorted to pushing promotional deals to retailers in an effort to boost sales; and (4) consequently, Defendant’s public statements were materially false and/or misleading and/or lacked a reasonable basis when made. Diplomat Pharmacy, Inc. (NYSE: DPLO) Class Period: February 26, 2018 - February 21, 2019, Deadline: April 25, 2019 For more info:www.bgandg.com/dplo The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)Class Period: August 4, 2016 - January 31, 2019 Deadline: April 26, 2019 For more info:www.bgandg.com/aveo The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in the June 2013; (2) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (3) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (4) as a result, AVEO’s public statements were materially false and misleading at all relevant times. Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com
AVEO CAG DPLO | globenewswire | about 6 years ago | Neutral

Profile

Diplomat Pharmacy Inc (DPLO)

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.As of February 7, 2020, Diplomat Pharmacy, Inc. operates as a subsidiary of OptumRx, Inc.

Exchange: NYSE

IPO Date: 10/10/2014

Sector: Other

Industry: Other

Employees: 2132

Address: 4100 South Saginaw Street 48507,Flint,USA

www.diplomatpharmacy.com

Quarterly Yearly

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	Totals
	Totals
Totals		-

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	Totals
	Totals
Totals		-

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	Totals
	Totals
Totals		-

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	Totals
	Totals
Totals		-

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	Totals
	Totals
Totals		-

&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;	Totals
	Totals
Totals		-

Profile

Free Stocks

Company

Features

Contact Us